In HER2+ breast cancer, Li and colleagues identified a four miRNA signature as a serum biomarker that may predict the therapeutic efficacy of the trastuzumab regimen in patients with HER2+ metastatic breast cancer [60]. This evidence concerns the gene ERBB2 and breast carcinoma.